Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative Bevacizumab and Trastuzumab with ABI-007 and Carboplatin in HER2+ Breast Cancer
NCT00392392Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Oct 2006
- Primary completion
- Apr 2008
- Modality
- Polymer-based Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab and nab-paclitaxel in breast cancer, sponsored by SCRI Development Innovations. Primary endpoint: Pathologic Complete Response Rate at 18 months. Started Oct 2006; status: completed.
02
Drugs
bevacizumabnab-paclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00392392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00392392.